In conclusion, these new discoveries for the inhibitory role of IGFBP-3 in obesity-induced insulin resistance and in the events occurring in the early stages of atherosclerosis, set the stage for a potential therapeutic role of IGFBP-3 in various aspects of metabolic syndrome. The gene discussed is IGFBP3; the disease is obesity disorder.